HI
UNCY icon

Harbour Investments’s Unicycive Therapeutics UNCY Stock Holding History

Harbour Investments’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469 Hold
100
– – ﹤0.01% 4384
2026
Q1 		$658 Hold
100
– – ﹤0.01% 4200
2025
Q4 		$577 Hold
100
– – ﹤0.01% 3535
2025
Q3 		$436 Hold
100
– – ﹤0.01% 3531
2025
Q2 		$477 Buy
+100
New +$618 ﹤0.01% 3382

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Harbour Investments's UNCY Position: Q2 2026 in Review

Harbour Investments held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 100 shares worth $469. The position accounts for ﹤0.01% of the portfolio, ranked #4384.

Harbour Investments first reported a position in UNCY in Q2 2025 and has held it in 5 quarters since. The position peaked at $658 in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Harbour Investments held 100 shares of Unicycive Therapeutics worth $469 as of Q2 2026.
  • Harbour Investments left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4384 holding.
  • Harbour Investments first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Harbour Investments's Unicycive Therapeutics position peaked at $658 in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.